0758 GMT - Haleon's full-year results are solid, with a 2025 outlook in line with consensus forecasts, RBC Capital Markets analysts say in a note. The British consumer-health company's 2024 results came in slightly ahead of consensus, despite analysts' and investors' concerns around a depressed North American flu season in 4Q, they say. For 2025, the company has guided for organic revenue growth to be in the range of 4% to 6% and organic operating profit growth ahead of sales growth. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 27, 2025 02:58 ET (07:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。